Ipca Laboratories Ltd
IPCALAB
Company Profile
Business description
Ipca Laboratories Ltd is a pharmaceutical company. The company's principal activity is the Development, Manufacturing, and Marketing of Pharmaceuticals Products. The company's API products include Atenolol (anti-hypertensive), Chloroquine Phosphate (anti-malarial), Chlorthalidone (diuretic), Furosemide (diuretic), Hydroxychloroquine Sulphate (DMARD), Losartan. The company has only one reportable primary business segment, pharmaceuticals.
Contact
No. 48, 123 AB, 125 & 126 Kandivli Industrial Estate
Kandivli (West)
MumbaiMH400067
INDT: +91 2262105000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2026
Employees
23,236
Stocks News & Analysis
stocks
How I lost all my savings through a poor investment decision
With first timers at risk of poor investment decisions and an interest in speculative stocks, I explore my biggest investing mistake.
stocks
Chart of the Week: Morningstar’s forecast for CSL’s future
We see gross margin expansion on efficiencies and limited tariff impact
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,070.50 | 41.00 | 0.45% |
| CAC 40 | 7,827.45 | 44.57 | -0.57% |
| DAX 40 | 23,666.81 | 55.48 | 0.23% |
| Dow JONES (US) | 46,121.28 | 171.50 | -0.37% |
| FTSE 100 | 9,250.43 | 27.11 | 0.29% |
| HKSE | 26,605.33 | 86.68 | 0.33% |
| NASDAQ | 22,497.86 | 75.62 | -0.33% |
| Nikkei 225 | 45,698.48 | 68.17 | 0.15% |
| NZX 50 Index | 13,123.67 | 57.64 | -0.44% |
| S&P 500 | 6,637.97 | 18.95 | -0.28% |
| S&P/ASX 200 | 8,778.70 | 40.80 | 0.47% |
| SSE Composite Index | 3,859.62 | 5.98 | 0.16% |